LLYELI LILLY & Co

NYSE lilly.com


$ 889.94 $ 4.93 (0.56 %)    

Tuesday, 18-Jun-2024 10:04:22 EDT
QQQ $ 484.95 $ -0.25 (-0.05 %)
DIA $ 389.22 $ 0.64 (0.16 %)
SPY $ 547.68 $ 0.47 (0.08 %)
TLT $ 93.84 $ -0.11 (-0.12 %)
GLD $ 215.05 $ 0.44 (0.21 %)
$ 885.01
$ 887.83
$ 890.00 x 109
$ 0.00 x 0
$ 884.01 - $ 890.23
$ 431.12 - $ 892.20
2,532,240
na
799.87B
$ 0.57
$ 130.31
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eli-lilly-and-company-form4-filing-shows-lilly-endowment-inc-bought-15022-shares-at-average-price-of-88247share

- SEC Filing

 cantor-fitzgerald-reiterates-overweight-on-eli-lilly-and-co-maintains-885-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.

 whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

 jpmorgans-500m-venture-capital-fund-bets-big-on-weight-loss-drugs-theyre-all-the-rage

JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.

 fda-grants-traditional-approval-to-selpercatinib-for-advanced-ret-fusion-positive-thyroid-cancer-in-patients-2-and-older-previously-received-accelerated-approval-for-patients-12-and-older-in-2020

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-ret-fusion-positive-thyroid-cancer

 cantor-fitzgerald-reiterates-overweight-on-eli-lilly-and-co-maintains-885-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.

 humans-clamor-for-weight-loss-drugs-but-the-next-users-could-be-pets

Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pa...

Core News & Articles

- Goldman Sachs Conference

Core News & Articles

- Goldman Sachs Conference

 jim-cramer-sees-eli-lilly-as-more-than-a-one-trick-pony-after-fda-advisors-back-its-alzheimers-drug-its-ultimately-headed-to-a-trillion-dollar-valuation

Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent end...

 eli-lillys-donanemab-gains-favorable-fda-advisory-verdict-boosting-stock-potential-says-bofa-analyst

Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish o...

 cantor-fitzgerald-reiterates-overweight-on-eli-lilly-and-co-maintains-885-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.

Core News & Articles

https://www.statnews.com/2024/06/11/google-verily-glp1-weight-loss-drugs-lightpath-onduo/